Breakspear Road South Harefield, Uxbridge Middlesex, UB9 6LS England
Tel: 01895 626000 Fax: 01895 672429

MATERIAL SAFETY DATA SHEET

Schering-Plough provides the information contained herein in good faith but makes no representation as to its comprehensiveness or accuracy. Individuals receiving the information must exercise their independent judgement in determining its appropriateness for a particular purpose.

SCHERING-PLOUGH MAKES NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS OR IMPLIED, OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE INFORMATION SET FORTH HERE IN OR TO THE PRODUCT TO WHICH THE INFORMATION REFERS. ACCORDINGLY, SCHERING-PLOUGH WILL NOT BE RESPONSIBLE FOR THE DAMAGES RESULTING FROM USE OR RELIANCE UPON THIS INFORMATION.

1. Identification of Substance or Preparation			
Product: GLETVAX™ 6			
Synonyms:			
Application: For pregnant gilts and sows for protection of piglets against E.Coli diarrhoea and C1 perfringens type C necrotising infectious enteritis.			
Company Undertaking Identification: Schering-Plough			
2. Composition/Information on Ingredients			
Active Ingredients:			
E.Coli antigens:			
Cl perfringens toxoids:			
K88ab Beta derived from Type B			
K88ac Beta derived from Type C			
K99 Epsilon derived from Type D 987P			
All > 20 units per ml			

Hazardous Components: None

Other Ingredients: Formaldehyde Thiomersal

3. Hazards Identification

Gletvax 6 presents little or no hazard to man or the environment under normal conditions of use.

4. First Aid

Eyes: Holding eyelids apart rinse immediately with copious amounts of clean water for at least 15-20 minutes.

Skin: Wash hands immediately after use with plenty of soap and water.

Ingestion: If accidentally enters the mouth, do not swallow, spit out and wash mouth with plenty of water and seek immediate medical treatment.

Inhalation: Minimal risk of exposure.

Other: Although the contents of dead non oil adjuvant vaccines are unlikely to cause reactions, occasional individual hypersensitivity cannot be ruled out. Also because of the way in which these products are used there is a risk of introducing infections from the general environment.

If there are any signs of hypersensitivity such as a rash, swelling, difficulty in breathing or other systemic signs, consult a Doctor immediately. Ensure that tetanus vaccination is up to date. Swelling at the injection site due to infection may occur in the days following self-injection and in such cases consult a Doctor.

Always take this data sheet when seeking medical advice, and show to Doctor or Nurse treating you.

5. Fire Fighting Measures

Extinguishing Media: As appropriate to source & type of fire.

Fire & Explosion Hazards: None.

Protective Measures: The fire officer in charge should be notified of the product (name, type, quantity) involved.

6. Accidental Release Measures (Spillage)

Personal Precautions: Not determined.

Environmental Precautions: Not determined.

Recovery: Absorb spillage onto cloth and dispose of as indicated in Section 13.

7. Storage & Handling (in normal use)

Storage: Store at temperatures between +2°C and +6°C.

Protect from light. Do not freeze.

General: Keep out of reach of children.

Part used containers of the vaccine should be discarded at the end of the days operations.

Handling: Read instructions before use.

Shake well before use.

Wash hands after use.

Syringes and needles should be sterilised before use and the injection should be made through an area of clean dry skin taking precautions against contamination.

8. Exposure/Control/Personal Protection (normal use)

Occupational: Not determined.

Engineering Measures: Not determined.

Personal Protective Equipment: Not determined.

Respiratory: Not determined.

Hand: Not determined.

Eye: Not determined.

Other: None.

9. Physical/Chemical Properties

Appearance: A fluid vaccine with a precipitate which suspends on shaking.

Odour: Not determined.

Not determined	Viscosity:	Not determined
Not determined	Freeze Thaw Recovery:	Not determined
Not determined	Boiling Point (or range):	Not determined
	Not determined	Not determined Freeze Thaw Recovery:

Auto Flammability:	Not determined	Explosive Limit Upper:	Not determined
Vapour Pressure:	Not determined	Explosive Limit Lower:	Not determined
Solubility:	Not determined	Relative Density (SG):	Not determined
Other:	None	Partition Coefficient:	Not determined

10. Stability & Reactivity

Stability: Stable under the recommended storage conditions.

Conditions to Avoid: Avoid extremes of temperature. Avoid direct light.

Materials to Avoid: None.

Recommended Materials for Equipment: Not determined.

Hazardous Decomposition Products

None known.

11. Toxicological Information

Acute Effects: Not determined.

Eyes: No toxic risk.

Skin: No toxic risk.

Ingestion: Not determined.

Inhalation: Minimal risk of exposure.

Chronic Effects: Not determined.

12. Ecological Information

Mobility: Not determined.

Persistence & Degradability: Not determined.

Bio-accumulation: Not determined.

Aquatic Toxicity: Not determined.

13. Disposal Considerations

Spillages, unused product and used containers should be collected by a reputable waste disposal

contractor for disposal at an approved waste disposal site.

14. Transport Information

Packaging (size & description): Boxes of 50ml.

Transport Classification: Nil.

Substance ID No.: 0

Proper Shipping Name: Nil.

ICAO/IATA/IMDG Class: Nil.

Subsidiary Risk: Nil.

Packing Group: Nil.

ADR Class: Nil.

Transport Hazard Symbol: Nil

Emergency Action Code: Nil.

Other: None.

15. Regulatory Information

Supply classification names & symbols

Risk Phrases & Regulations

Risk Phrases: N/A.

Safety Phrases: S2: Keep out of the reach of children.

S3: Store between +2°C and +8°C.

For animal treatment only.

Legal Category in UK:

To be sold or supplied only in a registered pharmacy by or under the supervision of a pharmacist or in accordance with Article 3 of the Medicines (Veterinary Drug), (Pharmacy & Merchants List) Order (PML).

16. Other Information

As with all vaccines occasionally hypersensitivity reactions can occur. Prompt subcutaneous administration of adrenalin may relieve the condition.